24 results about "Dermatomyositis" patented technology

The invention provides an ELISA (Enzyme Linked Immunosorbent Assay) kit for detecting an anti-MDA5 antibody and a preparation method of the ELISA kit. According to the kit, full-length human MDA5 protein (1025 amino acids) expressed by a cell-free protein expression system under the low-temperature condition of 22 DEG C is adopted as a coating antigen, and a disulfide bond enhancer E6820 is added into the system to promote correct folding of the protein. The kit comprises a microwell plate coated with a full-length MDA5 antigen, an enzyme-labeled anti-human IgG secondary antibody, a standard substance with the concentration range of 1-243 ng / mL, a chromogenic substrate and an optimized confining liquid system. The invention solves the problem of insufficient sensitivity caused by the use of fragment antigens in the prior art, and can be used for early diagnosis and illness monitoring of dermatomyositis-related interstitial lung diseases.

The invention relates to an MDA5 humanized monoclonal antibody as well as a preparation method and application thereof. The amino acid sequences of CDR1, CDR2 and CDR3 of a heavy chain of the antibody respectively comprise sequences shown as SEQ ID NO: 6-SEQ ID NO: 8, and the amino acid sequences of CDR1, CDR2 and CDR3 of a light chain respectively comprise a sequence shown as SEQ ID NO: 9 and sequences shown as DNN and SEQ ID NO: 10. The human monoclonal antibody is successfully screened, has high activity, good stability and accurate specific binding capacity for MDA5, is expected to become a new sharp tool in the fields of diagnosis, monitoring and treatment of dermatomyositis and related complications thereof, and brings a new opportunity for solving the medical problems.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation in the skin, e.g., atopic dermatitis, eczema other than atopic dermatitis, hidradenitis suppurativa, vitiligo, alopecia areata, scleroderma (including systemic sclerosis), dermatomyositis, epidermolysis bullosa, mastocytosis, keloids, acne, rosacea, or bullous pemphigoid, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody (Afimkibart).

The application belongs to the technical field of biological medicine, and particularly relates to application of a reagent for detecting anti-DLAT autoantibody in preparation of a product for detecting and / or diagnosing immune-mediated necrotizing myopathy. Experiments prove that DLAT can be used as a recognition antigen of an immune-mediated necrotizing myopathy related autoantibody, DLAT is a target point of the immune-mediated necrotizing myopathy autoantibody, the reactivity of the anti-DLAT autoantibody with the related antigen in dermatomyositis is 0%, the reactivity of the anti-DLAT autoantibody with other antigens HMGCR and SRP of the immune-mediated necrotizing myopathy is 0%, the anti-DLAT autoantibody is a new biological marker of the immune-mediated necrotizing myopathy, and the immune-mediated necrotizing myopathy can be detected and / or diagnosed.

The present disclosure provides methods related to treatment of a chronic immune-mediated disease of the skin and muscles. In particular, the present disclosure provides methods for the oral administration of a JAK inhibitor, or a pharmaceutically acceptable salt thereof for the treatment of dermatomyositis.

The invention provides a marker for prognosis of anti-MDA5 antibody positive dermatomyositis related interstitial pneumonia and application thereof, the marker is the proportion of CX3CR1 + CD14 + mononuclear cells in PBMC, and the marker is helpful for early recognition of high-risk patients, convenient for timely adjustment of therapeutic schedules and prevention of disease deterioration. The method for detecting the proportion of the CX3CR1 + CD14 + monocytes in the PBMC is mature and rapid, and can be used for multiple times of detection in different stages of diseases and dynamically monitoring the change of the illness state. The detection result of the proportion of the CX3CR1 + CD14 + monocytes in the PBMC is presented in a numerical form, the objectivity is high, the method is not influenced by the experience of an operator, and compared with subjective judgment of clinical symptoms and signs, the proportion of the CX3CR1 + CD14 + monocytes in the PBMC can be used as a prognostic marker to quantitatively evaluate the severity and treatment response of diseases, and an objective basis is provided for clinical decision making.

This invention provides a biomarker for predicting the prognosis of anti-MDA5 antibody-positive dermatomyositis-associated interstitial pneumonia and its application. The biomarker is CX3CR1 in PBMCs. + CD14 + The proportion of monocytes helps in the early identification of high-risk patients, facilitating timely adjustments to treatment plans and preventing disease progression. CX3CR1 in PBMCs... + CD14 + The method for detecting monocyte proportion is mature and rapid, allowing for multiple tests at different stages of the disease to dynamically monitor disease changes. CX3CR1 in PBMCs... + CD14 + The results of monocyte proportion detection are presented in numerical form, which is highly objective and unaffected by the operator's experience. Compared with subjective judgment based on clinical symptoms and signs, CX3CR1 in PBMCs... + CD14 + The proportion of monocytes, as a prognostic marker, can quantitatively assess disease severity and treatment response, providing an objective basis for clinical decision-making.

This disclosure relates to compounds of formula (I-1) or (I-2): This relates to TIFF2026513962000575.tif74102. The compounds of this disclosure can inhibit the activity of tyrosine kinase 2 (TYK2), for example, in inflammation, autoimmune diseases, neuroinflammation, arthritis, rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, lupus nephritis, arthritis, osteoarthritis, gouty arthritis, pain, fever, pulmonary sarcoidosis, silicosis, cardiovascular disease, atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury, cardiomyopathy, stroke, ischemia, reperfusion injury, cerebral edema, head trauma, neurodegeneration, liver disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, nephritis, retina It is useful in treating diseases or disorders such as inflammation, retinopathy, macular degeneration, glaucoma, diabetes (type 1 and type 2), diabetic neuropathy, viral and bacterial infections, myalgia, endotoxin shock, toxic shock syndrome, autoimmune diseases, osteoporosis, multiple sclerosis, endometriosis, menstrual pain, vaginitis, candidiasis, cancer, fibrosis, obesity, muscular dystrophy, polymyositis, dermatomyositis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, vitiligo, alopecia, Alzheimer's disease, skin flushing, eczema, psoriasis, atopic dermatitis, and sunburn. This disclosure further provides a method for preparing the compound.

The present application relates to a kind of MDA5 antibody and its preparation method and application.The present application selects the human-derived monoclonal antibody of anti-MDA5, with high activity, good stability and strong binding specificity, provides new tool for the diagnosis, monitoring and treatment of dermatomyositis and its complications.

Use of compounds of formula I and formula II, and specifically relates to use of compound A1-A52, B1-B5, or C1-C36 in the preparation of a drug for treating and / or preventing an inflammatory or immune disease are provided. Compounds of A1-A52, B1-B5, or C1-C36 are used in the preparation of a drug for treating and / or preventing diseases such as rheumatoid arthritis, atopic dermatitis, hidradenitis suppurativa, vitiligo, dermatomyositis, alopecia areata, urticaria, multiple myositis, an interstitial lung disease, systemic lupus erythematosus, systemic sclerosis, and psoriasis.

The present application relates to a kind of anti-MDA5 humanized antibody and its preparation method and application.The amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain of the antibody respectively include the sequences shown in SEQ ID NO.1~SEQ ID NO.3, the amino acid sequences of CDR1, CDR2 and CDR3 of light chain respectively include the sequence shown in SEQ ID NO.4, QDN and the sequence shown in SEQ ID NO.5.The present application obtains anti-MDA5 human monoclonal antibody by screening, the activity of the antibody is high, stability is good, and has the specificity of stronger binding MDA5, provides new tool for dermatomyositis and its complication diagnosis, monitoring and treatment etc..

The invention relates to an anti-MDA5 humanized antibody as well as a preparation method and application thereof. The amino acid sequences of CDR1, CDR2 and CDR3 of a heavy chain of the antibody respectively comprise sequences as shown in SEQ ID NO.1-SEQ ID NO.3, and the amino acid sequences of CDR1, CDR2 and CDR3 of a light chain of the antibody respectively comprise a sequence as shown in SEQ ID NO.4 and sequences as shown in QDN and SEQ ID NO.5. The anti-MDA5 human monoclonal antibody is obtained through screening, the antibody is high in activity and good in stability, the specificity for combining MDA5 is high, and a new tool is provided for diagnosis, monitoring, treatment and the like of dermatomyositis and complications of dermatomyositis.

The invention relates to an MDA5 targeting antibody as well as a preparation method and application thereof. The anti-MDA5 human monoclonal antibody is obtained through screening, the antibody is high in activity and good in stability, the specificity for combining MDA5 is high, and a new tool is provided for diagnosis, monitoring, treatment and the like of dermatomyositis and complications of dermatomyositis.

The present disclosure relates to sequence selective deoxyribonucleic acid (DNA) binding compounds comprising a polyamide moiety configured to bind a DNA sequence. The invention also relates pharmaceutical compositions comprising the compounds, and methods of using the compounds for restoring expression of autoimmune regulator (AIRE) gene. The invention further relates to pharmaceutical compositions comprising the compounds, and methods of using the compounds for and treating an autoimmune disease (e.g., Addison disease, Celiac disease, dermatomyositis. Graves disease, Hashimoto thyroiditis, inflammatory bowel disease, multiple sclerosis (MS), myasthenia gravis, pernicious anemia, reactive arthritis, Sjogren syndrome, systemic lupus erythematosus, and type I diabetes). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention discloses an application of betulinic acid 28-O-beta-D-glucoside (BA-6 for short) in preparation of a medicine for preventing and treating skin inflammation. The problems that an existing medicine for treating dermatitis is limited in curative effect, slow in effect taking, multiple in side effect, high in long-term use risk, large in individual difference, high in treatment cost, likely to cause immunoreaction and the like are solved. The invention discloses application of BA-6 in prevention and treatment of atopic dermatitis, contact dermatitis, eczema, rash, psoriasis, lupus erythematosus, papule squamous skin disease, pityriasis rosea, seborrheic dermatitis, pemphigus, celestial abscess, acne, tinea corporis, impetigo, SAPHO syndrome, hidradenitis suppurativa, dermatitis caused by drugs, lichen planus, pityriasis rubra pilaris, vitiligo, prurigo nodularis, dermatitis caused by drugs, and the like for the first time. The traditional Chinese medicine composition can be used for treating skin diseases, systemic sclerosis, hidradenitis suppurativa, granulomatous skin diseases, vitiligo, dermatomyositis, chronic skin itch and alopecia areata, and has the technical progress of obviously improving skin erythema, papule, edema, scale, moss and ulceration symptoms.

Compositions of recombinant intravenous immunoglobulin (rIVIG) proteins and methods for purifying and using rIVIG proteins. The compositions comprise oligomeric Fc molecules that bind Fc receptors with high avidity. The rIVIG proteins are useful as immunomodulatory molecules to treat immune disorders, including autoimmune diseases, such as refractory immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, lupus, Graves' disease, Kawasaki disease, dermatomyositis, myasthenia gravis, Guillain-Barre syndrome, autoimmune hemolytic anemia, and other immune and inflammatory conditions. The rIVIG proteins are also useful as immunomodulatory agents for patients to reduce immune rejection of organ transplants, stem cell transplants, and bone marrow transplants. In addition, the present invention provides rIVIG proteins of non-human origin for use in veterinary immune disorders, such as canine rIVIG proteins for treating dogs with autoimmune hemolytic anemia, immune thrombocytopenic purpura, rheumatoid arthritis, or other canine immune disorders.

The application relates to an antibody targeting MDA5 and a preparation method and application thereof. A human monoclonal antibody targeting MDA5 is screened, the antibody has high activity, good stability, and high specificity in binding MDA5, and provides a new tool for the diagnosis, monitoring and treatment of dermatomyositis and its complications.

The invention relates to an MDA5 antibody as well as a preparation method and application thereof. The anti-MDA5 human monoclonal antibody screened by the invention has high activity, good stability and strong binding specificity, and provides a new tool for diagnosis, monitoring and treatment of dermatomyositis and complications thereof.

The present disclosure provides methods associated with treating chronic immune-mediated skin and muscle diseases. The present disclosure provides, inter alia, methods of treating dermatomyositis by oral administration of a JAK inhibitor or a pharmaceutically acceptable salt thereof.

The present invention relates to the compound of Formula 1 and STING antagonists, for example, systemic lupus erythematosus (SLE), (monogeneic and digeneic) interferon disorders (including STING-associated vascular disorders that develop in infancy (SAVI), Eicardi-Goutier syndrome (AGS), COPA syndrome, and familial chilblain lupus), type 1 interferon disorders with mutations in DNASE2 or ATAD3A genes, age-related macular degeneration (AMD), retinopathy, glaucoma, amyotrophic lateral sclerosis (ALS), diabetes mellitus, obesity, and inflammatory bowel disease. This relates to the use of these as STING antagonists for the treatment of diseases selected from the group consisting of intestinal diseases (IBD), chronic obstructive pulmonary disease (COPD), Bloom syndrome, Sjögren's syndrome, Parkinson's disease, heart failure and cancer, systemic sclerosis (SSc), dermatomyositis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), acute exacerbation of chronic liver failure (ACLF), interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), age-related / muscle disorders, sepsis, heart failure, rheumatoid arthritis and osteoarthritis. JPEG2026510538000418.jpg45150

The application provides an application of a neutrophil TRIM21 splicing regulator in preparation of a drug for treating dermatomyositis. It is found for the first time that TRIM21 splicing in neutrophils is related to the onset of dermatomyositis, and it is further confirmed that TRIM21 exists in key splicing sensitive sites located between I40 and S41 and between V43 and G44. A protective strategy capable of inhibiting TRIM21 splicing is developed for the sites, which can provide a potential treatment scheme for patients with dermatomyositis combined with interstitial pneumonia or severe inflammation in clinic.

The invention provides a biomarker for resisting MDA5 positive dermatomyositis and application of the biomarker. The invention discloses an application of an HLA-DQA1 * 06: 01 gene as a biomarker for resisting MDA5 positive dermatomyositis in preparation of products related to diagnosis of the MDA5 positive dermatomyositis. The biomarker can be used for diagnosis, illness state evaluation or prognosis prediction of anti-MDA5 positive dermatomyositis, is beneficial to further research on pathogenesis or genetic characteristics of anti-MDA5 positive dermatomyositis, and helps to optimize a disease model and improve the early detection rate of diseases.

The present application relates to a kind of MDA5 humanization monoclonal antibody and its preparation method and application.The amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain of the antibody respectively include the sequences shown in SEQ ID NO:6~SEQ ID NO:8, the amino acid sequences of CDR1, CDR2 and CDR3 of light chain respectively include the sequence shown in SEQ ID NO:9, DNN and the sequence shown in SEQ ID NO:10.The present application successfully screens a human monoclonal antibody, which has high activity, good stability and precise specific binding capacity to MDA5, and is expected to become a new tool in the diagnosis, monitoring and treatment of dermatomyositis and its related complications, and bring new opportunities for the attack of these medical problems.